这三款产品分别为瑞可妥、瑞百莱和美比瑞，均适用于精神分裂症的治疗。恩华和信将负责以上产品在 中国大陆的独家经销与商业化，公司则继续持有该三款产品的资产权、注册证及全部知识产权等权利， 并负责产品的生产和供货。协议期限为10年，恩华将一次性支付公司不可退还的2000万美元授权费。 近日，绿叶制药发布公告，公司与恩华药业（002262）的附属公司江苏恩华和信医药营销有限公司签署 合作协议，授予恩华和信三款抗精神病药长效针剂产品在中国大陆地区的独家商业化权利。 ...

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

Group 1 - Fenglong Co., Ltd. announced that its controlling shareholder will change to UBTECH, and the stock will resume trading [12][13] - Victory Energy has experienced a continuous increase in stock price for nine consecutive trading days, with a cumulative increase of 135.86%, and may apply for a trading suspension if the price continues to rise [4] - Dongbai Group issued a stock price fluctuation announcement, indicating potential risks of significant price drops after recent increases [10] Group 2 - Enhua Pharmaceutical's wholly-owned subsidiary signed a $20 million exclusive commercial cooperation agreement with Green Leaf Pharmaceutical for three long-acting antipsychotic products in mainland China, with a sales target of at least 2.7 billion RMB from 2026 to 2035 [2] - Longpan Technology plans to increase the planned production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [2] - Jiangsu Zhanchin, a company in which Hongda Electronics holds a 13.79% stake, has submitted an IPO application, but the progress remains uncertain [3] Group 3 - Jizhi Co., Ltd. intends to acquire at least 51% of Zhejing Pumai Technology to enhance its capabilities in the robotics sector [4] - Nanshan Aluminum established a wholly-owned subsidiary in Hainan with an investment of 5 million RMB to improve regional industrial layout and expand high-end aluminum product development [5] - Sany Heavy Energy plans to use up to 9.5 billion RMB of its own funds for entrusted wealth management in 2026 [9] Group 4 - Zongtai Automobile reached a settlement with two bank creditors to avoid large financial disputes and facilitate the release of frozen assets [11] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, but the project faces risks of underperformance [6] - Guangyang Co., Ltd. signed a strategic cooperation agreement with Konghui Automotive to advance its business layout in the intelligent driving sector [7]

作为对绿叶制药及绿叶嘉奥根据《协议》所授予的权利和许可的对价，恩华和信应向绿叶制药及绿叶嘉 奥一次性支付合计2000万美元不可退还的授权对价，该授权对价均由恩华和信以自有或自筹资金支付。 根据《协议》约定，恩华和信将在2026-2035年期间完成对绿叶制药及绿叶嘉奥合作产品总计不低于27 亿元人民币的销售额(含税)。绿叶制药及绿叶嘉奥应依据恩华和信对许可产品的采购和销售情况，向恩 华和信支付相应的服务费。 恩华药业（002262）(002262.SZ)发布公告，公司全资子公司江苏恩华和信医药营销有限公司(以下简 称"恩华和信")分别与山东绿叶制药有限公司(以下简称"绿叶制药")及其子公司绿叶嘉奥制药石家庄有限 公司(以下简称"绿叶嘉奥")达成产品《独家商业合作协议》。 恩华和信将分别获得绿叶制药的注射用利培酮微球(II)(以下简称"瑞可妥")、棕榈酸帕利哌酮注射液(II) (以下简称"瑞百莱")及绿叶嘉奥的棕榈酸帕利哌酮注射液(以下简称"美比瑞")共三款抗精神病药长效针 剂产品在中国大陆地区开展推广、销售及其他商业化活动的独家权益。 此次获得绿叶制药及绿叶嘉奥独家授权在中国大陆地区商业化权益的三款长效针剂形成 ...

智通财经APP讯， 恩华药业(002262.SZ)发布公告，公司全资子公司江苏恩华和信医药营销有限公司(以 下简称"恩华和信")分别与山东绿叶制药有限公司(以下简称"绿叶制药")及其子公司绿叶嘉奥制药石家庄 有限公司(以下简称"绿叶嘉奥")达成产品《独家商业合作协议》。 此次获得绿叶制药及绿叶嘉奥独家授权在中国大陆地区商业化权益的三款长效针剂形成差异化的产品组 合，可以全面覆盖精神分裂症患者全病程各个阶段的治疗所需，具备显著的临床价值。中枢神经系统 (CNS)是公司的核心战略领域之一，公司此次与绿叶制药及绿叶嘉奥达成战略合作，标志着国内中枢神 经系统(CNS)领域两家领先企业强强联合，双方将共同推进在精神分裂症治疗市场的深度布局，有利于 增进这些产品在基层医疗中心的覆盖，帮助更多患者获得规范化治疗，减轻疾病负担。 作为对绿叶制药及绿叶嘉奥根据《协议》所授予的权利和许可的对价，恩华和信应向绿叶制药及绿叶嘉 奥一次性支付合计2000万美元不可退还的授权对价，该授权对价均由恩华和信以自有或自筹资金支付。 根据《协议》约定，恩华和信将在2026-2035年期间完成对绿叶制药及绿叶嘉奥合作产品总计不低于27 亿元人民币 ...

每经AI快讯，恩华药业（SZ 002262，收盘价：25.1元）12月24日晚间发布公告称，公司第七届第六次 董事会临时会议于2025年12月24日在徐州市经济技术开发区龙湖西路31号恩华科技大厦20楼会议室召 开。会议审议了《关于增选1名董事会战略委员会成员并修订 <董事会战略委员会实施细则> 的议案》 等文件。 2025年1至6月份，恩华药业的营业收入构成为：工业占比85.81%，医药商业占比13.08%，其他贸易及 劳务占比0.58%，其他业务占比0.52%。 每经头条（nbdtoutiao）——微信聊天遭老板监视，杀毒软件"失明"，员工隐私被系统性采集！软件商 公开售卖"监控神器"，称已服务多家企业 （记者 曾健辉） 截至发稿，恩华药业市值为255亿元。 ...

（1）作为对绿叶制药及绿叶嘉奥根据《协议》所授予的权利和许可的对价，恩华和信应向绿叶制药及 绿叶嘉奥一次性支付合计2000万美元不可退还的授权对价，该授权对价均由恩华和信以自有或自筹资金 支付。（2）根据《协议》约定，恩华和信将在2026-2035年期间完成对绿叶制药及绿叶嘉奥合作产品总 计不低于27亿元人民币的销售额（含税）。（3）根据《协议》约定，绿叶制药及绿叶嘉奥应依据恩华 和信对许可产品的采购和销售情况，向恩华和信支付相应的服务费。 格隆汇12月24日丨恩华药业(002262.SZ)公布，公司全资子公司江苏恩华和信医药营销有限公司（简 称"恩华和信"）分别与山东绿叶制药有限公司（简称"绿叶制药"）及其子公司绿叶嘉奥制药石家庄有限 公司（简称"绿叶嘉奥"）达成产品《独家商业合作协议》，恩华和信将分别获得绿叶制药的注射用利培 酮微球（II）（简称"瑞可妥®"）、棕榈酸帕利哌酮注射液（II）（简称"瑞百莱®"）及绿叶嘉奥的棕榈 酸帕利哌酮注射液（简称"美比瑞®"）共三款抗精神病药长效针剂产品（以下称"合作产品"）在中国大 陆地区开展推广、销售及其他商业化活动的独家权益。 ...

根据协议，恩华和信应向绿叶制药及绿叶嘉奥一次性支付合计2000万美元不可退还的授权对价，并在 2026—2035年期间完成对合作产品总计不低于27亿元人民币的销售额(含税)，绿叶制药及绿叶嘉奥应依 据恩华和信对许可产品的采购和销售情况，向恩华和信支付相应的服务费。 人民财讯12月24日电，恩华药业（002262）公告，全资子公司恩华和信与绿叶制药及其子公司绿叶嘉奥 达成产品《独家商业合作协议》，恩华和信将获得绿叶制药的注射用利培酮微球(II)、棕榈酸帕利哌酮 注射液(II)及绿叶嘉奥的棕榈酸帕利哌酮注射液共三款抗精神病药长效针剂产品在中国大陆地区开展推 广、销售及其他商业化活动的独家权益。合作期限自协议生效日起至2035年12月31日止。 ...

每经AI快讯，12月24日，恩华药业（002262）(002262.SZ)公告称，公司全资子公司恩华和信与绿叶制 药及其子公司绿叶嘉奥达成产品《独家商业合作协议》，恩华和信将获得绿叶制药的注射用利培酮微球 (II)、棕榈酸帕利哌酮注射液(II)及绿叶嘉奥的棕榈酸帕利哌酮注射液共三款抗精神病药长效针剂产品在 中国大陆地区开展推广、销售及其他商业化活动的独家权益。合作期限自《协议》生效日起至2035年12 月31日止。根据《协议》，恩华和信应向绿叶制药及绿叶嘉奥一次性支付合计2000万美元不可退还的授 权对价，并在2026-2035年期间完成对合作产品总计不低于27亿元人民币的销售额(含税)。该交易不构成 关联交易，亦不构成重大资产重组。 ...

江苏恩华药业股份有限公司 年报信息披露重大差错责任追究制度 （2025 年 12 月 24 日修订） 第一章 总则 第一条 为了进一步提高江苏恩华药业股份有限公司（以下简称"公司"）的规范运 作水平，提高年报信息披露的质量和透明度，增强年报信息披露的真实性、准确性、完整 性和及时性，加大对年报信息披露责任人的问责力度，根据中国证监会《上市公司信息披 露管理办法》《上市公司治理准则》《深圳证券交易所股票上市规则》《深圳证券交易所上 市公司自律监管指引第 1 号—主板上市公司规范运作》等有关法律、行政法规、规范性文 件及《公司章程》《公司信息披露管理制度》的相关要求，结合公司实际情况，特制定本 制度。 第二条 本制度用于规范在公司年报信息披露工作中，有关人员不履行或者不正确履 行职责、义务或因其他个人原因，对公司年报信息披露造成重大差错时的责任追究与处理， 适用于公司董事、高级管理人员、各子公司负责人、控股股东、实际控制人以及与年报信 息披露工作有关的其他人员。 第三条 本制度所指年报信息披露重大差错是指足以影响年报使用人对公司财务状况、 经营成果和现金流量以及年报的其它内容做出正确判断的重大差错，包括但不限于年 ...